Ironfist Therapeutics’ 177Lu — Tamrada™ Doubles Survival with Anti — PD — 1 Therapy in Checkpoint — Resistant Pancreatic Cancer Model
For best results when printing this announcement, please click on link below: Ironfist Therapeutics’ (177)Lu-Tamrada™ Doubles Survival with Anti-PD-1 Therapy in Checkpoint-Resistant Pancreatic Cancer Model Tamrada Theranostic Pair, (64)Cu PET Imaging Agent and (177)Lu Therapeutic Agent, Progressing to Clinical Trials (64)Cu-Tamrada Dosimetry Demonstrates 240-Fold Safety Factor for Planned First-in-Human Study Ironfist Therapeutics (“Ironfist”), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor-associated macrophages without a targeting ligand, will present positive preclinical proof-of-concept results for (177)Lu-Tamrada at the 39(th) Annual Congress of the European Association of Nuclear Medicine (EANM’26), taking place October 17—21, 2026, in Vienna, Austria. In an orthotopic syngeneic model of pancreatic cancer resistant to anti-PD-1 therapy, (177)Lu-Tamrada in combination with anti-PD-1 therapy more than doubled survival compared to anti-PD-1 therapy alone. “These preclinical results continue to support our strategy of treating the immune-suppressing microenvironment in cancers,” said Jeffrey L. Cleland, PhD, Chie
For best results when printing this announcement, please click on link below: Ironfist Therapeutics’ (177)Lu-Tamrada™ Doubles Survival with Anti-PD-1 Therapy in Checkpoint-Resistant Pancreatic Cancer Model Tamrada Theranostic Pair, (64)Cu PET Imaging Agent and (177)Lu Therapeutic Agent, Progressing to Clinical Trials (64)Cu-Tamrada Dosimetry Demonstrates 240-Fold Safety Factor for Planned First-in-Human Study Ironfist Therapeutics (“Ironfist”), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor-associated macrophages without a targeting ligand, will present positive preclinical proof-of-concept results for (177)Lu-Tamrada at the 39(th) Annual Congress of the European Association of Nuclear Medicine (EANM’26), taking place October 17—21, 2026, in Vienna, Austria.
In an orthotopic syngeneic model of pancreatic cancer resistant to anti-PD-1 therapy, (177)Lu-Tamrada in combination with anti-PD-1 therapy more than doubled survival compared to anti-PD-1 therapy alone. “These preclinical results continue to support our strategy of treating the immune-suppressing microenvironment in cancers,” said Jeffrey L. Cleland, PhD, Chief Executive Officer of Ironfist Therapeutics.
” Oral Presentation Details: Targeted Killing of Tumor Associated Macrophages with a Novel (177)Lu Lu-Nanomedicine Prolongs Survival and Unlocks Checkpoint Inhibition in an Orthotopic Pancreatic Cancer Model Oral presentation OP-482 | Session 1104: M2M Track — TROP Session — Translational Molecular Imaging & Therapy Committee: Advances in Combination Therapies Monday, October 19, 2026, 5:35 PM | Hall E2 Pancreatic ductal adenocarcinoma is a difficult-to-treat cancer resistant to checkpoint inhibition and generally considered protected from the immune system. Long-term survival is limited with current treatments.
The pancreatic cancer results are consistent with previous positive single-agent results, including tumor inhibition in xenograft and orthotopic 4T1 triple-negative breast cancer models and in PSMA-negative prostate cancer models. “By killing tumor-associated macrophages (TAMs) and suppressor cells, (177)Lu-Tamrada exposes the tumor to the immune system to halt tumor growth and promote survival,” said S. Sakura Minami, PhD, Vice President of Translational Medicine and Nonclinical Development. “The cytotoxic effects are confined to the tumor, as shown by localized double-strand DNA breaks, leaving other organs and healthy tissue intact.
” e-Poster Details: Radiation Dosimetry, Chemistry and Formulation of a Novel (64)Cu Cu-Nanomedicine Radiotracer that Selectively Targets Tumor Associated Macrophages e-Poster Number: EP-0072 Session: EP-05, During Congress, October 17—21, 2026 Session Title: A: Preclinical and Translational Studies › A1 Medical Preclinical › A15a Preclinical Dosimetry The e-Poster reports that dosimetry for the imaging agent (64)Cu-Tamrada identified red marrow as the dose-limiting organ, with a 240-fold safety factor above the highest proposed human dose of 200 MBq.
“Radiopharmaceuticals have drawn significant interest from large pharma, and Tamrada offers something different: a target-independent way to reach the tumor microenvironment across many cancer types,” said Mukul Agarwal, Chief Business Officer of Ironfist Therapeutics. P. com). About Tamrada Tamrada is designed from the novel nanomedicine technology of hydroxyl dendrimers invented at Johns Hopkins University.
The nanomedicine component of Tamrada is comparable in size to an antibody fragment, does not leave the vasculature except in tumors, and has renal and biliary clearance without metabolism. (177)Lu-Tamrada provides an additional benefit of a bystander effect by killing adjacent tumor cells. The nanomedicine in Tamrada is amenable to modifications to create a pipeline of radiopharmaceuticals with different radioisotopes beyond lutetium-177, such as actinium-225 or other alpha emitters. About Ironfist Therapeutics Ironfist Therapeutics is advancing a new class of nanomedicine radiopharmaceuticals that selectively target tumor-associated macrophages.
Ironfist’s precision medicine approach to treat any tumor with TAMs has the potential to change the paradigm in cancer treatment by unlocking the immune system. Ironfist is a sister company of Programmable Medicine, leveraging the same hydroxyl dendrimer platform to develop radiopharmaceuticals for oncology. com: Inquiries Company and Investors Jeffrey L. com)